Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.67 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.65 |
| ▸ | ATM | Q13315 | 3/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | GLA | P06280 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 2/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30881266 | 1.00 | LMNA (0.68) | LMNASMN1; SMN2KMT2AGPBAR1ATM | |
| SCHEMBL6644159 | 0.91 | LMNA (0.56) | LMNASMN1; SMN2KMT2AGPBAR1ATM | |
| SCHEMBL3451560 | 0.90 | TSHR (0.75) | LMNASMN1; SMN2KMT2AGPBAR1MEN1 | |
| SCHEMBL899628 | 0.89 | LMNA (0.68) | LMNASMN1; SMN2KMT2AGPBAR1ATM | |
| SCHEMBL10520781 | 0.89 | LMNA (0.68) | LMNASMN1; SMN2KMT2AGPBAR1ATM | |
| SCHEMBL7184918 | 0.88 | TSHR (0.82) | LMNASMN1; SMN2KMT2AGPBAR1ATM | |
| SCHEMBL10332625 | 0.88 | LMNA (0.67) | LMNASMN1; SMN2KMT2AGPBAR1ATM | |
| Anthranilic Acid SCHEMBL7870197 | 0.87 | LMNA (0.62) | LMNASMN1; SMN2KMT2AGPBAR1ATM | |
| SCHEMBL11893412 | 0.85 | ALDH1A1 (0.72) | LMNASMN1; SMN2KMT2AGPBAR1ATM | |
| SCHEMBL14519854 | 0.85 | KMT2A (0.67) | LMNASMN1; SMN2KMT2AGPBAR1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 147 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102964356-A | Synthesis method of flucloxacillin sodium | HEZE RUIZHI TECHNOLOGY DEV CO LTD | 2013-03-13 | — | — | CN | claimed |
| CN-102702227-A | Preparation method for flucloxacillin sodium | HEBEI HUARI PHARMACEUTICAL CO LTD | 2012-10-03 | — | — | CN | claimed |
| US-20040010005-A1 | Stereoselective process for preparing cylcohexyl amine derivatives | BARNETT CHARLES JACKSON (US) | 2004-01-15 | — | — | US | claimed |
| EP-1322652-A1 | STEREOSELECTIVE PROCESS FOR PREPARING CYCLOHEXYL AMINE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2003-07-02 | — | — | EP | claimed |
| WO-2002024705-A1 | STEREOSELECTIVE PROCESS FOR PREPARING CYCLOHEXYL AMINE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2002-03-28 | — | — | WO | claimed |
| CN-117964622-A | Novel isoxazole compound and preparation method and application thereof | 河北科技大学 | 2024-05-03 | — | — | CN | disclosed |
| CN-115819228-A | Synthetic method of 2-aryl-2-cyclohexanedione enol ester compound | 南方医科大学 | 2023-03-21 | — | — | CN | disclosed |
| EP-4074708-A1 | 1-(4-(ISOXAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-METHYLPROPAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS IL-7 AND IFN-GAMMA INHIBITORS FOR TREATING AUTOIMMUNE DISEASES AND CHRONIC INFLAMMATION | Immunic AG (DE) | 2022-10-19 | — | — | EP | disclosed |
| EP-3679034-B1 | 1-(4-(ISOXAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-METHYLPROPAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS IL-7 AND IFN-GAMMA INHIBITORS FOR TREATING AUTOIMMUNE DISEASES AND CHRONIC INFLAMMATION | IMMUNIC AG (DE) | 2022-06-01 | — | — | EP | disclosed |
| US-11292788-B2 | IL-17 and IFN-gamma inhibition for the treatment of autoimmune diseases and chronic inflammation | IMMUNIC AG (DE) | 2022-04-05 | — | — | US | disclosed |
| CN-109400630-B | Synthetic method of flucloxacillin sodium | 浙江普洛得邦制药有限公司 | 2021-07-02 | — | — | CN | disclosed |
| US-20210061796-A1 | IL-17 and IFN-gamma inhibition for the treatment of autoimmune diseases and chronic inflammation | IMMUNIC AG (DE) | 2021-03-04 | — | — | US | disclosed |
| EP-1067928-A1 | METHODS FOR INHIBITING MRP1 | ELI LILLY AND COMPANY (US) | 2001-01-17 | — | — | EP | disclosed |
| WO-1999051236-A1 | METHODS FOR INHIBITING MRP1 | ELI LILLY AND COMPANY (US) | 1999-10-14 | — | — | WO | disclosed |
| WO-1999051227-A1 | METHODS FOR INHIBITING MRP1 | ELI LILLY AND COMPANY (US) | 1999-10-14 | — | — | WO | disclosed |
| WO-1999051228-A1 | METHODS FOR INHIBITING MRP1 | ELI LILLY AND COMPANY (US) | 1999-10-14 | — | — | WO | disclosed |
| EP-0265185-A2 | Cephalosporins, processes for their preparation and pharmaceutical compositions containing them | BEECHAM GROUP PLC (GB) | 1988-04-27 | — | — | EP | disclosed |
| US-4179511-A | Antibacterial 3-(5-tetrazolyl) penam compounds | PFIZER INC. (US) | 1979-12-18 | — | — | US | disclosed |
| US-4143039-A | ANTIBACTERIAL 3-(5-TETRAZOLYL)PENAM COMPOUNDS | PFIZER INC. (US) | 1979-03-06 | — | — | US | disclosed |
| US-4115385-A | PENICILLINS | PFIZER INC. (US) | 1978-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210061796-A1 | IL-17 and IFN-gamma inhibition for the treatment of autoimmune diseases and chronic inflammation | IFNG, IL17A, IFNAR1 | LMNA 3556/4885SMN1; SMN2 4231/4885KMT2A 1459/4885 |
| US-20040010005-A1 | Stereoselective process for preparing cylcohexyl amine derivatives | ALKBH3, AZI2, ALKBH1 | LMNA 864/4885SMN1; SMN2 2439/4885KMT2A 411/4885 |
| US-11292788-B2 | IL-17 and IFN-gamma inhibition for the treatment of autoimmune diseases and chronic inflammation | IFNG, IL17A, IFNAR1 | LMNA 3556/4885SMN1; SMN2 4231/4885KMT2A 1459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.